Developer docs
API playgroundTry for free, no card

Search company profiles

MiMedx Group

Full company profile

uuid00026zr

Namestring
MiMedx Group
Legal namestring
MIMEDX Group, Inc.
Websiteurl
mimedx.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

MiMedx Group, Inc. (NASDAQ: MDXG) is a publicly traded therapeutic biologics company headquartered in Marietta, Georgia, that develops, manufactures, and commercializes placental tissue allograft products for wound care and surgical applications. The company's core technology is the proprietary PURION processing method applied to donated human placental tissue, yielding Dehydrated Human Amnion Chorion Membrane (DHACM) and Lyophilized Human Amnion Chorion Membrane (LHACM) products including EPIFIX, EPICORD, EPIEFFECT, CHORIOFIX, AMNIOFIX, and AMNIOCORD. These products are sold across two segments: Advanced Wound Solutions for chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions for soft tissue repair across multiple surgical specialties. The portfolio is supported by over 85 U.S. patents, FDA registration, AATB accreditation, and state tissue bank licenses across seven states.

The company generates revenue through one-time product sales to healthcare providers, with reimbursement sourced from Medicare, Medicaid, and commercial payers. Go-to-market combines direct field sales (20+ Field Reimbursement Managers), GPO agreements with Premier and Vizient, and exclusive distribution partnerships (Regen Lab USA for RegenKit-Wound Gel, Gel4Med for G4Derm Plus). The MIMEDX CONNECT digital platform supports ordering and insurance verification. Key customer segments include wound care clinicians, surgeons across 10+ specialties, hospital systems and IDNs, and underserved uninsured patients through a Patient Assistance Program. The company's revenue base contracted sharply in Q1 2026 (down 33% YoY to $59M) following Medicare reimbursement reforms effective January 2026 that drove a 60% decline in the wound care segment, while the surgical segment grew 13% YoY. In response, management initiated a $40M cost reduction program including a 15% workforce reduction targeting Q3 2026 breakeven.

Short descriptiontext

MiMedx Group (NASDAQ: MDXG) is a publicly traded therapeutic biologics company that develops and commercializes placental tissue allograft products for wound care and surgical applications, serving healthcare providers across the United States through direct sales, GPO agreements, and exclusive distribution partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMarietta, United States
HQ citystring
Marietta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wound care biologics, placental tissue allografts, amniotic membrane products, regenerative medicine devices, surgical recovery grafts
Industry3 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine / Wound Care Biologics
Social media profiles4 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Advanced Wound Care Products
TypeOne Time License
Description

Sales of placental allograft products (EPIFIX, EPICORD, EPIEFFECT, EPIXPRESS, CELERA, EMERGE, CHORIOFIX) for chronic wound treatment including diabetic foot ulcers and venous leg ulcers. Q1 2026 wound sales dropped 60% YoY to $22.6M due to Medicare reimbursement headwinds.

ainvest.com
2Advanced Surgical Products
TypeOne Time License
Description

Sales of surgical allograft products (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) for surgical applications including burn, trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular procedures. Grew 13% YoY in Q1 2026.

finance.yahoo.com
3RegenKit-Wound Gel Distribution
TypeTransaction Fee
Description

Exclusive U.S. distribution of RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel (HCPCS code G0465) covered nationally by CMS for diabetic chronic wounds.

ca.investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others
Pricing details1 tier
1Product catalog with multiple size configurations and billing units
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products priced per unit/size configuration. Medicare billing units specified (e.g., 14mm disc = 2 billing units, 7cm x 7cm sheet = 49 billing units). Reimbursement varies by payer and site of service (HOPD vs physician office).

mimedx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 16 records shown
1EPIFIX
Description

Dehydrated Human Amnion/Chorion Membrane product for wound care applications

mimedx.com
+15 more records
Core offering1 text field

MiMedx Group manufactures and distributes PURION-processed placental tissue allograft products for wound care and surgical recovery. Its portfolio spans Advanced Wound Solutions (EPIFIX, EPICORD, EPIEFFECT, CELERA, EMERGE, EPIXPRESS, CHORIOFIX, RegenKit-Wound Gel) targeting chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) serving surgical applications across burn/trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular specialties. Products are sold to healthcare providers in the United States with reimbursement through Medicare, Medicaid, and commercial payers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 92% complete wound closure at 6 weeks for diabetic foot ulcers treated with EPIFIX
+4 more records
Product overview1 text field

MiMedx Group is a therapeutic biologics company and pioneer in placental biologics offering a broad portfolio of advanced wound care and surgical products. The product portfolio consists of two main categories: Advanced Wound Solutions (EPIFIX, EPICORD, EPIXPRESS, CELERA, EMERGE, CHORIOFIX, RegenKit-Wound Gel) designed for wound care clinicians treating chronic and hard-to-heal wounds; and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) for surgical applications across multiple specialties including burn and trauma, foot and ankle, colorectal, gynecologic, orthopedic, plastic, spine, thyroid, and vascular surgery. All placental products are processed using proprietary PURION methodology and are backed by extensive clinical evidence including the largest body of Level I evidence among placental allograft products.

Product and service16 records
1EPIFIX
CategoryAdvanced Wound Solutions
Description

Dehydrated Human Amnion/Chorion Membrane (DHACM) allograft for advanced wound care, specifically indicated for diabetic foot ulcers and venous leg ulcers. Supported by extensive Level I clinical evidence including multiple RCTs.

2EPICORD
CategoryAdvanced Wound Solutions
Description

Dehydrated Human Umbilical Cord allograft for wound care applications, providing a protective barrier for acute and chronic wounds. In a multicenter RCT, EPICORD demonstrated 81% complete wound closure at 12 weeks versus standard of care.

3EPIEFFECT
CategoryAdvanced Wound Solutions
Description

Lyophilized Human Placental-Based Allograft Membrane designed as a protective barrier for wound treatment. Currently undergoing CAMPAIGN clinical trial evaluating performance against standard of care.

4CELERA
CategoryAdvanced Wound Solutions
Description

Dehydrated Human Amniotic Membrane Allograft for wound care applications, offering another placental tissue-based option for clinicians.

5EMERGE
CategoryAdvanced Wound Solutions
Description

Dual Membrane Placental Derived Matrix providing a protective barrier for acute and chronic wounds.

6EPIXPRESS
CategoryAdvanced Wound Solutions
Description

Lyophilized Human Amniotic Membrane Allograft in fenestrated sheet form for wound care applications.

7CHORIOFIX
CategoryAdvanced Wound Solutions
Description

Lyophilized Human Placental Allograft with unique triple-layer construction, the thickest in the MiMedx portfolio. Designed as a protective barrier for acute and chronic wounds including complex tunneling wounds, featuring uniform dual-sided design.

8RegenKit-Wound Gel
CategoryAdvanced Wound Solutions
Description

FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. Distributed exclusively by MiMEDX in the U.S. under HCPCS code G0465 with national CMS coverage.

9AMNIOFIX
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft product for surgical applications in multiple surgical specialties.

10AMNIOCORD
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft for surgical applications.

11AMNIOBURN
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft specifically indicated for burn and trauma surgical applications.

12AMNIOEFFECT
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft for surgical applications.

13AXIOFILL
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft for surgical applications.

14HELIOGEN
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft for surgical applications.

15G4Derm Plus
CategoryAdvanced Surgical Solutions
Description

Flowable wound matrix product using self-assembling peptide technology. MiMEDX holds exclusive distribution rights in the United States. Launched nationwide with GPO agreements with Premier and Vizient.

16Hydrelix
CategoryAdvanced Surgical Solutions
Description

Placental tissue allograft for surgical applications.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-09
Description

Distribution collaboration with Summit Products Group and MiMEDX for G4Derm Plus Biomimetic Matrix (BMM) product. Summit Products Group distributes G4Derm Plus alongside MiMEDX's portfolio, leveraging MiMEDX's established GPO and IDN contracting capabilities to accelerate hospital-system adoption in acute-care and surgical-suite markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-22
Description

Exclusive U.S. distribution agreement for RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. Product nationally covered by CMS under HCPCS code G0465, complementing MiMedx's Advanced Wound Care portfolio and strengthening competitive position ahead of January 1, 2026 CMS reimbursement changes.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-01
Description

Exclusive manufacturing and supply agreement granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications, expanding MiMedx's product portfolio into new technology areas.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Premier Graft Purchasing Program partnership enabling healthcare providers to access advanced skin substitutes with no financial risk, deferred payment model, and clinical documentation support. Includes EPIFIX, EPIEFFECT, EPICORD, EPIXPRESS, and REGENKIT products for private practices (Places of Service 11, 12, 13, & 32).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Group purchasing organization agreements securing access to hospital networks for G4Derm Plus national launch. Agreements enable distribution across participating Premier and Vizient member hospital systems, providing group purchasing contracting for MiMedx's advanced wound care portfolio.

6CAMPAIGN Clinical Trial Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration for EPIEFFECT product evaluation against standard of care in treating non-healing diabetic foot ulcers. Interim results from 71-88 enrolled patients demonstrating superior performance over SOC, supporting insurance coverage and future regulatory approvals.

globenewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Diversified MedTech incumbent with a major wound care franchise (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel) and a surgical/regenerative tissue portfolio overlapping MiMedx's surgical solutions across multiple specialties.

TypeBroad incumbent
Description

Global wound care leader with advanced dressings (Allevyn, Acticoat), negative pressure wound therapy (PICO), and skin substitute products that compete directly with MiMedx's EPIFIX family in the chronic wound segment.

3Regen Lab SA
TypeDirect peer
Description

Swiss-based regenerative medicine company whose RegenKit-Wound Gel MiMedx now distributes exclusively in the U.S. Direct peer in PRP-based wound healing products; demonstrates the technology platform that MiMedx is leveraging to diversify away from placental allografts.

TypeDirect peer
Description

Non-profit tissue processor and MiMedx's direct competitor in placental and dermal allografts (Dermacell, Arthroflex), with overlapping wound care and surgical reconstruction use cases and similar AATB-accredited processing capabilities.

TypeBroad incumbent
Description

Advanced wound care portfolio (Aquacel, DuoDERM) with growing presence in skin substitutes and tissue regeneration, overlapping with MiMedx's hospital-based wound care channels through GPO contracts.

6Amniox Medical (TissueTech)
TypeDirect peer
Description

Direct competitor in cryopreserved and dehydrated amniotic membrane allografts (CLARIX, NEOX) for wound care and surgical applications, addressing the same podiatry, orthopedic, and surgical segments as MiMedx.

TypeDirect peer
Description

Direct competitor in skin substitutes and advanced wound care, marketing Apligraf (the head-to-head comparator for EPIFIX) and Dermagraft, plus the PuraPly wound matrix portfolio. Closest publicly traded comparable for placental and cellular allograft wound care economics.

TypeBroad incumbent
Description

Owner of KCI's V.A.C. negative pressure wound therapy franchise and former employer of several MiMedx executives (Kim Moller, John Harper, Eric Smith). Competes across wound care and surgical recovery with a far broader portfolio.

TypeEmerging player
Description

Emerging player in drug-coated balloons and surface coating technologies for vascular and wound applications; competes in adjacent surgical intervention segments where MiMedx's AMNIOFIX and AMNIOBURN are positioned.

TypeBroad incumbent
Description

Major wound and skin care franchise (Biatain, Comfeel) competing in advanced wound dressings; recently expanded into surgical biologics with the Kerecis fish-skin graft acquisition, a direct amniotic membrane substitute.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MiMedx Group

Regenerative Medicine / Wound Care Biologicsmimedx.com

MiMedx Group (NASDAQ: MDXG) is a publicly traded therapeutic biologics company that develops and commercializes placental tissue allograft products for wound care and surgical applications, serving healthcare providers across the United States through direct sales, GPO agreements, and exclusive distribution partnerships.

What MiMedx Group does

MiMedx Group, Inc. (NASDAQ: MDXG) is a publicly traded therapeutic biologics company headquartered in Marietta, Georgia, that develops, manufactures, and commercializes placental tissue allograft products for wound care and surgical applications. The company's core technology is the proprietary PURION processing method applied to donated human placental tissue, yielding Dehydrated Human Amnion Chorion Membrane (DHACM) and Lyophilized Human Amnion Chorion Membrane (LHACM) products including EPIFIX, EPICORD, EPIEFFECT, CHORIOFIX, AMNIOFIX, and AMNIOCORD. These products are sold across two segments: Advanced Wound Solutions for chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions for soft tissue repair across multiple surgical specialties. The portfolio is supported by over 85 U.S. patents, FDA registration, AATB accreditation, and state tissue bank licenses across seven states.

The company generates revenue through one-time product sales to healthcare providers, with reimbursement sourced from Medicare, Medicaid, and commercial payers. Go-to-market combines direct field sales (20+ Field Reimbursement Managers), GPO agreements with Premier and Vizient, and exclusive distribution partnerships (Regen Lab USA for RegenKit-Wound Gel, Gel4Med for G4Derm Plus). The MIMEDX CONNECT digital platform supports ordering and insurance verification. Key customer segments include wound care clinicians, surgeons across 10+ specialties, hospital systems and IDNs, and underserved uninsured patients through a Patient Assistance Program. The company's revenue base contracted sharply in Q1 2026 (down 33% YoY to $59M) following Medicare reimbursement reforms effective January 2026 that drove a 60% decline in the wound care segment, while the surgical segment grew 13% YoY. In response, management initiated a $40M cost reduction program including a 15% workforce reduction targeting Q3 2026 breakeven.

MiMedx Group firmographics

Firmographics
Name
MiMedx Group
Legal name
MIMEDX Group, Inc.
Website
https://mimedx.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
501–1,000 employees
Short description
MiMedx Group (NASDAQ: MDXG) is a publicly traded therapeutic biologics company that develops and commercializes placental tissue allograft products for wound care and surgical applications, serving healthcare providers across the United States through direct sales, GPO agreements, and exclusive distribution partnerships.
Ownership category
akta.pro rank

MiMedx Group industry classification

Industry
Product category
Regenerative Medicine / Wound Care Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Wound care biologics
  • Placental tissue allografts
  • Amniotic membrane products
  • Regenerative medicine devices
  • Surgical recovery grafts

Where MiMedx Group is headquartered

Location

Headquarters

HQ city
Marietta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MiMedx Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

  1. Advanced Wound Care Products: Sales of placental allograft products (EPIFIX, EPICORD, EPIEFFECT, EPIXPRESS, CELERA, EMERGE, CHORIOFIX) for chronic wound treatment including diabetic foot ulcers and venous leg ulcers. Q1 2026 wound sales dropped 60% YoY to $22.6M due to Medicare reimbursement headwinds.
  2. Advanced Surgical Products: Sales of surgical allograft products (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) for surgical applications including burn, trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular procedures. Grew 13% YoY in Q1 2026.
  3. RegenKit-Wound Gel Distribution: Exclusive U.S. distribution of RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel (HCPCS code G0465) covered nationally by CMS for diabetic chronic wounds.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goProduct catalog with multiple size configurations and billing units

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

MiMedx Group product offering

Product offering

Core offering

MiMedx Group manufactures and distributes PURION-processed placental tissue allograft products for wound care and surgical recovery. Its portfolio spans Advanced Wound Solutions (EPIFIX, EPICORD, EPIEFFECT, CELERA, EMERGE, EPIXPRESS, CHORIOFIX, RegenKit-Wound Gel) targeting chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) serving surgical applications across burn/trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular specialties. Products are sold to healthcare providers in the United States with reimbursement through Medicare, Medicaid, and commercial payers.

Product overview

MiMedx Group is a therapeutic biologics company and pioneer in placental biologics offering a broad portfolio of advanced wound care and surgical products. The product portfolio consists of two main categories: Advanced Wound Solutions (EPIFIX, EPICORD, EPIXPRESS, CELERA, EMERGE, CHORIOFIX, RegenKit-Wound Gel) designed for wound care clinicians treating chronic and hard-to-heal wounds; and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) for surgical applications across multiple specialties including burn and trauma, foot and ankle, colorectal, gynecologic, orthopedic, plastic, spine, thyroid, and vascular surgery. All placental products are processed using proprietary PURION methodology and are backed by extensive clinical evidence including the largest body of Level I evidence among placental allograft products.

Differentiator

Problem solved

Functional benefit

Brands

  • EPIFIX: Dehydrated Human Amnion/Chorion Membrane product for wound care applications
  • EPICORD
  • EPIEFFECT
  • EPIXPRESS
  • CELERA
  • EMERGE
  • CHORIOFIX
  • AMNIOFIX
  • AMNIOCORD
  • AMNIOBURN
  • AMNIOEFFECT
  • AXIOFILL
  • HELIOGEN
  • G4Derm Plus
  • Hydrelix
  • RegenKit-Wound Gel

Products and services

  • EPIFIX Dehydrated Human Amnion/Chorion Membrane (DHACM) allograft for advanced wound care, specifically indicated for diabetic foot ulcers and venous leg ulcers. Supported by extensive Level I clinical evidence including multiple RCTs.
  • EPICORD Dehydrated Human Umbilical Cord allograft for wound care applications, providing a protective barrier for acute and chronic wounds. In a multicenter RCT, EPICORD demonstrated 81% complete wound closure at 12 weeks versus standard of care.
  • EPIEFFECT Lyophilized Human Placental-Based Allograft Membrane designed as a protective barrier for wound treatment. Currently undergoing CAMPAIGN clinical trial evaluating performance against standard of care.
  • CELERA Dehydrated Human Amniotic Membrane Allograft for wound care applications, offering another placental tissue-based option for clinicians.
  • EMERGE Dual Membrane Placental Derived Matrix providing a protective barrier for acute and chronic wounds.
  • EPIXPRESS Lyophilized Human Amniotic Membrane Allograft in fenestrated sheet form for wound care applications.
  • CHORIOFIX Lyophilized Human Placental Allograft with unique triple-layer construction, the thickest in the MiMedx portfolio. Designed as a protective barrier for acute and chronic wounds including complex tunneling wounds, featuring uniform dual-sided design.
  • RegenKit-Wound Gel FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. Distributed exclusively by MiMEDX in the U.S. under HCPCS code G0465 with national CMS coverage.
  • AMNIOFIX Placental tissue allograft product for surgical applications in multiple surgical specialties.
  • AMNIOCORD Placental tissue allograft for surgical applications.
  • AMNIOBURN Placental tissue allograft specifically indicated for burn and trauma surgical applications.
  • AMNIOEFFECT Placental tissue allograft for surgical applications.
  • AXIOFILL Placental tissue allograft for surgical applications.
  • HELIOGEN Placental tissue allograft for surgical applications.
  • G4Derm Plus Flowable wound matrix product using self-assembling peptide technology. MiMEDX holds exclusive distribution rights in the United States. Launched nationwide with GPO agreements with Premier and Vizient.
  • Hydrelix Placental tissue allograft for surgical applications.

Quantifiable outcome

  • 92% complete wound closure at 6 weeks for diabetic foot ulcers treated with EPIFIX
  • +4 more outcomes

Companies that use MiMedx Group

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

MiMedx Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MiMedx Group partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Gel4Med, Inc.coreChannel Partner/ Reseller/ Distributor · 9 February 2026Distribution collaboration with Summit Products Group and MiMEDX for G4Derm Plus Biomimetic Matrix (BMM) product. Summit Products Group distributes G4Derm Plus alongside MiMEDX's portfolio, leveraging MiMEDX's established GPO and IDN contracting capabilities to accelerate hospital-system adoption in acute-care and surgical-suite markets.
  • Regen Lab USA LLCcoreChannel Partner/ Reseller/ Distributor · 22 December 2025Exclusive U.S. distribution agreement for RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. Product nationally covered by CMS under HCPCS code G0465, complementing MiMedx's Advanced Wound Care portfolio and strengthening competitive position ahead of January 1, 2026 CMS reimbursement changes.
  • Regenity BiosciencescoreTechnology or Integration · 1 March 2024Exclusive manufacturing and supply agreement granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications, expanding MiMedx's product portfolio into new technology areas.
  • WoundGenexcoreChannel Partner/ Reseller/ DistributorPremier Graft Purchasing Program partnership enabling healthcare providers to access advanced skin substitutes with no financial risk, deferred payment model, and clinical documentation support. Includes EPIFIX, EPIEFFECT, EPICORD, EPIXPRESS, and REGENKIT products for private practices (Places of Service 11, 12, 13, & 32).
  • Premier and VizientcoreChannel Partner/ Reseller/ DistributorGroup purchasing organization agreements securing access to hospital networks for G4Derm Plus national launch. Agreements enable distribution across participating Premier and Vizient member hospital systems, providing group purchasing contracting for MiMedx's advanced wound care portfolio.
  • CAMPAIGN Clinical Trial NetworkcoreStrategic or Co-development PartnerClinical trial collaboration for EPIEFFECT product evaluation against standard of care in treating non-healing diabetic foot ulcers. Interim results from 71-88 enrolled patients demonstrating superior performance over SOC, supporting insurance coverage and future regulatory approvals.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

MiMedx Group competitors and assessment

Company assessment

Broad incumbents

  • Integra LifeSciences: Diversified MedTech incumbent with a major wound care franchise (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel) and a surgical/regenerative tissue portfolio overlapping MiMedx's surgical solutions across multiple specialties.
  • Smith+Nephew: Global wound care leader with advanced dressings (Allevyn, Acticoat), negative pressure wound therapy (PICO), and skin substitute products that compete directly with MiMedx's EPIFIX family in the chronic wound segment.
  • ConvaTec: Advanced wound care portfolio (Aquacel, DuoDERM) with growing presence in skin substitutes and tissue regeneration, overlapping with MiMedx's hospital-based wound care channels through GPO contracts.
  • 3M Health Care (KCI): Owner of KCI's V.A.C. negative pressure wound therapy franchise and former employer of several MiMedx executives (Kim Moller, John Harper, Eric Smith). Competes across wound care and surgical recovery with a far broader portfolio.
  • Coloplast: Major wound and skin care franchise (Biatain, Comfeel) competing in advanced wound dressings; recently expanded into surgical biologics with the Kerecis fish-skin graft acquisition, a direct amniotic membrane substitute.

Direct peers

  • Regen Lab SA: Swiss-based regenerative medicine company whose RegenKit-Wound Gel MiMedx now distributes exclusively in the U.S. Direct peer in PRP-based wound healing products; demonstrates the technology platform that MiMedx is leveraging to diversify away from placental allografts.
  • LifeNet Health: Non-profit tissue processor and MiMedx's direct competitor in placental and dermal allografts (Dermacell, Arthroflex), with overlapping wound care and surgical reconstruction use cases and similar AATB-accredited processing capabilities.
  • Amniox Medical (TissueTech): Direct competitor in cryopreserved and dehydrated amniotic membrane allografts (CLARIX, NEOX) for wound care and surgical applications, addressing the same podiatry, orthopedic, and surgical segments as MiMedx.
  • Organogenesis Holdings: Direct competitor in skin substitutes and advanced wound care, marketing Apligraf (the head-to-head comparator for EPIFIX) and Dermagraft, plus the PuraPly wound matrix portfolio. Closest publicly traded comparable for placental and cellular allograft wound care economics.

Emerging players

  • SurModics: Emerging player in drug-coated balloons and surface coating technologies for vascular and wound applications; competes in adjacent surgical intervention segments where MiMedx's AMNIOFIX and AMNIOBURN are positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

MiMedx Group social profiles

Digital presence

MiMedx Group compliance and trust

Trust signal

Compliance4 records

MiMedx Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MiMedx Group leadership team

Management profile

Number of profiles

Profiles8 records

MiMedx Group funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MiMedx Group M&A and investment

M&A and investment

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiMedx Group

What does MiMedx Group do?

MiMedx Group manufactures and distributes PURION-processed placental tissue allograft products for wound care and surgical recovery. Its portfolio spans Advanced Wound Solutions (EPIFIX, EPICORD, EPIEFFECT, CELERA, EMERGE, EPIXPRESS, CHORIOFIX, RegenKit-Wound Gel) targeting chronic wounds such as diabetic foot ulcers and venous leg ulcers, and Advanced Surgical Solutions (AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, HELIOGEN, G4Derm Plus, Hydrelix) serving surgical applications across burn/trauma, foot/ankle, colorectal, gynecologic, orthopedic, plastic, spine/neurosurgery, thyroid, and vascular specialties. Products are sold to healthcare providers in the United States with reimbursement through Medicare, Medicaid, and commercial payers.

Is MiMedx Group a public or private company?

MiMedx Group is a public company. It is classified as public and is currently operating.

When was MiMedx Group founded?

MiMedx Group was founded in 2008. It employs 501 to 1,000 people.

Where is MiMedx Group based?

MiMedx Group is headquartered in Marietta, United States, in the North America region.

How does MiMedx Group make money?

Three revenue lines are on record. Advanced Wound Care Products are the primary driver. The others are advanced Surgical Products and regenKit-Wound Gel Distribution.

Who are MiMedx Group's main competitors?

Broad incumbents on record are Integra LifeSciences, Smith+Nephew, ConvaTec, 3M Health Care (KCI) and Coloplast. Direct peers are Regen Lab SA, LifeNet Health, Amniox Medical (TissueTech) and Organogenesis Holdings. SurModics is listed as an emerging player.

Does MiMedx Group have an API?

No public API is recorded for MiMedx Group.

What industry is MiMedx Group in?

MiMedx Group's product category is Regenerative Medicine / Wound Care Biologics. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldMiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care StrugglesMiMedx Group reported $62 million in Q3 net sales, with surgical products generating $40 million and wound care struggling due to Medicare reimbursement cuts. The company is pursuing its Sanara MedTech acquisition, which would add over $100 million in annual revenue and open $4 billion in addressable markets. It expects the combined surgical business to account for about three-quarters of revenue.Medical BuyerSanara MedTech posts net loss of USD 1.3M in Q3 2026Sanara MedTech reported a Q3 2026 net loss of $1.3 million, with net revenue of $28.4 million, up 8% year-over-year. The company updated its full-year 2026 net revenue guidance to $110–115 million, down from $116–121 million. It also noted shareholder approval for a pending acquisition by MIMEDX.MarketBeatMiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care StrugglesMiMedx Group reported $62 million in Q3 net sales, with surgical products generating $40 million and growing 9% in revenue. The company is pursuing its Sanara MedTech acquisition, which would add over $100 million in annual revenue and open $4 billion in addressable markets. Wound care revenue was pressured by Medicare reimbursement changes, but the company expects combined surgical revenue to reach $400 million in the first year.Business & FinancialMIMEDX To Participate In Upcoming Investor ConferencesMIMEDX will participate in investor conferences on November 11 and 17, 2026, in New York, with webcast and in-person sessions. The company, a wound care and burn products provider, invites investors to meet senior management through their representatives.Stock TitanMIMEDX to Participate in Two Investor ConferencesMIMEDX announced that senior management will participate in the Canaccord MedTech forum on November 11, 2026, and the Craig-Hallum Alpha Select Conference on November 17, 2026, both in New York. Investors may contact their respective representatives to request meetings.MarketBeatMiMedx Group, Inc (NASDAQ:MDXG) Stock Rated "Moderate Buy" by Sell-Side BrokeragesMiMedx Group shares carry a consensus 'Moderate Buy' rating from seven brokerages, with an average 12-month price target of $8.14. The company reported a loss of $0.01 EPS and revenue of $62.28 million for the quarter, missing estimates. Institutional investors hold 79.15% of the stock.TradingViewMiMedx Group, Inc Stock 12‑Month Price Target Cut to $7.2, Implies 82% UpsideAnalysts' average price target for MiMedx Group fell from $7.4 to $7.2, implying about 82% upside from the Oct. 28 close. The consensus remains a Buy across five analysts, with targets ranging from $6 to $8 per share.MarketBeatMiMedx Group (NASDAQ:MDXG) Announces Earnings ResultsMiMedx Group reported Q3 EPS of $0.01 and revenue of $62.28 million, below the $68.56 million estimate. Surgical revenue grew 9% year over year, while total sales fell 45% to $62 million due to a 71% drop in wound-care revenue. The company expects high-single-digit surgical growth in Q4.MarketScreenerMiMedx Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026MiMedx Group reported Q3 2026 sales of $62.28 million, down from $113.73 million a year ago, and a net loss of $8.68 million versus net income of $16.75 million. For the nine months, sales fell to $185.64 million from $300.54 million, and net loss widened to $34.38 million from $33.39 million.MarketBeatWhat MiMedx Group (MDXG) Said on Its Q3 Earnings CallMiMedx Group reported Q3 net sales of $62 million, down 45% year over year, as wound care revenue fell 71% to $22 million while surgical revenue rose 9% to $40 million. The company expects Q4 surgical growth in the high-single digits and updated its 2026 standalone sales outlook to $250–260 million.